CEP
NKTR icon

Chicago Equity Partners’s Nektar Therapeutics NKTR Stock Holding History

Chicago Equity Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,541
Closed -$3.24M – 853
2018
Q3 		$3.24M Buy
3,541
+698
+25% +$596K 0.1% 290
2018
Q2 		$2.08M Sell
2,843
-1,093
-28% -$1.26M 0.06% 376
2018
Q1 		$6.27M Buy
+3,936
New +$5.07M 0.2% 149

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chicago Equity Partners's NKTR Position: Q4 2018 in Review

Chicago Equity Partners sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 3,541 shares — an estimated $3.24M sold.

Chicago Equity Partners first reported a position in NKTR in Q1 2018 and held it in 3 quarters. The position peaked at $6.27M in Q1 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Chicago Equity Partners reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 3,541 Nektar Therapeutics shares in Q4 2018, an estimated $3.24M.
  • Chicago Equity Partners first reported a position in Nektar Therapeutics in Q1 2018 and held it in 3 quarters.
  • Chicago Equity Partners's Nektar Therapeutics position peaked at $6.27M in Q1 2018.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Chicago Equity Partners's 13F filing for Q4 2018, filed 5 Feb 2019.